Cross Border Compliance with Attorney Benjamin L. England

Episode Summary:
Attorney Benjamin England, founder of FDAImports.com, delves into the intricacies of supply chain transparency in FDA-regulated importing. From FSMA-204 to the UFLPA, he highlights the critical need for importers to document ingredient origins and ensure compliance with FDA oversight. Learn how traceability plays a vital role in safeguarding against food safety events and recalls, offering essential insights for importers.
Key Timestamps:
00:00 – Introduction
03:45 – Supply Chain Transparency 2.0
06:10 – FSMA-204 Traceability Requirements
09:25 – Future Expansion of Traceability Demands
12:15 – CBP's UF LPA and Forced Labor Documentation
15:40 – Maintaining Records for FDA and CBP Compliance
18:55 – Final Takeaways and Recommendations
About the Show:
FDA Imports is your go-to resource for understanding the complexities of FDA regulations and compliance in cross-border supply chains. Join us as we unravel the nuances of import documentation and regulatory requirements to ensure your business stays ahead in the global trade landscape.

Episode Summary:In this insightful episode, Benjamin England, founder of FDA Imports and former FDA regulatory counsel, explores how artificial intelligence and predictive analytics are transforming the way the FDA and U.S. Customs evaluate imports. Ben breaks down how the PREDICT system—short for Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting—uses data-driven scoring to identify high-risk shipments and streamline inspections. He also discusses the role of machine learning in modern compliance systems, the critical importance of data accuracy for importers, and how technology continues to evolve the relationship between FDA, Customs, and other regulatory agencies.
Key Timestamps:00:01 – Show Introduction00:56 – What Is the PREDICT System and How Does It Work03:12 – Evolution of FDA’s Risk-Based Import Screening05:00 – Incorporation of AI and Evolutionary Algorithms in PREDICT07:42 – Comparing Early and Modern Screening Results09:55 – Importance of Data Consistency for Importers12:34 – Interagency Data Sharing Between FDA, Customs, and USDA15:06 – Practical Steps for Small Importers to Avoid Unnecessary Holds17:40 – The Future of AI and Human Judgment in FDA Inspections
About the Show:"FDA Imports: Cross Border Compliance" delves into the complex intersection of FDA oversight, Customs enforcement, and international trade. Each episode features expert insights from Benjamin England, who helps global businesses navigate evolving compliance challenges through practical strategies and regulatory expertise.

Episode Summary
In this episode of FDA Imports: Cross Border Compliance, attorney Benjamin L. England, founder of FDAImports.com and former FDA regulatory counsel, unpacks the complex world of private labeling and contract manufacturing. England explains how private label arrangements work in FDA-regulated industries, who holds responsibility at the border, and the hidden compliance risks brand owners often overlook. From contract structures to regulatory oversight, he provides a roadmap for U.S. brands sourcing overseas and highlights the pitfalls that can trigger costly FDA and Customs issues.
Key Timestamps
[00:01:00] What private labeling looks like in FDA-regulated industries[00:03:00] Who is legally responsible for compliance at the border[00:05:00] Common documentation and registration problems in private label arrangements[00:07:00] How formula or label changes by manufacturers can create risk for brand owners[00:09:30] What happens if shipments are detained and the brand owner isn’t listed as importer[00:11:00] How contracts can protect brand owners from regulatory risks[00:13:00] Why indemnification clauses don’t shield importers from FDA enforcement[00:15:00] Why many companies fail to draft contracts until after problems arise[00:17:00] Key advice for U.S. brands launching private label products sourced overseas
About the Show:
FDA Imports Cross-Border Compliance is a podcast hosted by attorney Benjamin L. England, founder of FDAImports.com. The show helps importers, exporters, and global businesses navigate the complex legal and regulatory landscape at the U.S. border. With expert insights on FDA, Customs, USDA, DEA, and trade compliance, listeners gain practical strategies to protect their products and keep supply chains moving.

Episode Summary:In this episode of FDA Imports: Cross Border Compliance, Benjamin England breaks down how the ongoing federal government shutdown is affecting the FDA and U.S. Customs and Border Protection. Drawing on his experience as a former FDA regulatory counsel, Benjamin explains how much of the FDA’s operations continue due to user fees and why import enforcement remains active even during a shutdown.
He outlines which inspections are still taking place, which types of products are being prioritized, and how the shutdown impacts imported goods ranging from foods and drugs to cosmetics and medical devices. Benjamin also discusses how companies can manage communication delays with the FDA and Customs, what steps importers should take if their products are detained, and what to expect when the government eventually reopens.
Key Timestamps:00:55 – How the FDA continues operating during a government shutdown02:30 – The role of user fees and why most FDA activities remain functional04:20 – Which inspections and compliance functions are still active06:10 – Why high-risk imports like seafood and ready-to-eat foods remain top priority09:00 – How companies should handle delays and communication issues with the FDA11:15 – The government’s response to health emergencies and contaminated imports13:40 – How CBP manages inspections, seizures, and enforcement during a shutdown16:00 – What importers and exporters can expect once the government reopens
Show Description:Benjamin England provides an inside look at the real-world impact of a federal government shutdown on FDA and Customs operations. Despite the shutdown, he explains that the FDA continues to function at nearly 86% capacity, driven by user fees and essential import enforcement activities.
He highlights how FDA inspectors prioritize higher-risk imports, such as ready-to-eat foods and seafood potentially contaminated with Cesium-137, while lower-risk products like cosmetics and animal food experience fewer inspections. Benjamin also discusses how the FDA’s risk-based matrix determines where limited resources are allocated and how Customs continues to perform mandatory inspections.
For importers and manufacturers, Benjamin offers guidance on managing delays, communicating effectively with regulators, and ensuring compliance while operations are slowed. He warns that once the government reopens, backlogs and staffing shortages will likely extend delays for weeks or months. His advice emphasizes staying proactive, maintaining contact with compliance officers, and seeking experienced regulatory support to navigate the challenges.

Episode Summary
In this episode of FDA Imports: Cross Border Compliance, attorney Benjamin L. England, founder of FDAImports.com and former FDA regulatory counsel, breaks down the complexities of FDA import alerts. England explains what import alerts are, how companies get flagged, the risks of detention without physical examination, and what businesses must do to clear their products and restore compliance. He also shares real-world case examples, highlights industries most at risk, and provides practical strategies to reduce exposure to FDA enforcement.
Key Timestamps
[00:01:00] What FDA import alerts are and the industries they impact[00:03:00] The difference between one-time detention and detention without physical examination[00:05:00] Common reasons companies are added to the FDA import alert list[00:07:00] High-risk industries, products, and countries more frequently flagged[00:09:30] How companies are placed on import alerts and the lack of formal notice[00:11:00] Steps businesses must take to be removed from an import alert[00:13:00] Real case examples of companies removed from FDA alerts[00:15:00] Proactive strategies to monitor risks and avoid FDA red flags
About the Show:
FDA Imports Cross-Border Compliance is a podcast hosted by attorney Benjamin L. England, founder of FDAImports.com. The show helps importers, exporters, and global businesses navigate the complex legal and regulatory landscape at the U.S. border. With expert insights on FDA, Customs, USDA, DEA, and trade compliance, listeners gain practical strategies to protect their products and keep supply chains moving.

Episode Summary
In this episode of FDA Imports: Cross Border Compliance, attorney Benjamin L. England, founder of FDAImports.com and former FDA regulatory counsel, unpacks the critical role of country of origin declarations in international trade. He explains why origin determinations go beyond simple labeling, how they impact tariffs, duty evaluations, and compliance risks, and why companies must be diligent in documenting and reviewing their practices. England also explores the overlap of customs law, FDA and USDA oversight, and FTC enforcement when origin claims are made.
Key Timestamps
[00:01:00] What country of origin declarations are and why they matter under customs law[00:04:00] The role of free trade agreements and why origin has always been important for CBP[00:06:00] Differences in FDA vs. USDA concerns over product origin[00:09:30] CBP enforcement actions, penalties, and the use of prior disclosures[00:13:00] Common mistakes companies make in declaring origin and the risks of misclassification[00:16:00] “Made in the USA” claims and FTC enforcement on misleading labeling[00:18:00] Best practices for businesses: conducting origin evaluations, HTS classification, and documentation
About the Show:
FDA Imports Cross-Border Compliance is a podcast hosted by attorney Benjamin L. England, founder of FDAImports.com. The show helps importers, exporters, and global businesses navigate the complex legal and regulatory landscape at the U.S. border. With expert insights on FDA, Customs, USDA, DEA, and trade compliance, listeners gain practical strategies to protect their products and keep supply chains moving.

Episode Summary:In this episode of FDA Imports Cross-Border Compliance, regulatory attorney Benjamin L. England breaks down the evolving challenges importers face under shifting U.S. trade policies. With the return of Trump-era tariffs, FDA-regulated companies are encountering unexpected costs, heightened inspection activity, and more frequent supply chain disruptions. Ben shares insights on the growing role of FDA and Customs collaboration, labeling enforcement trends, and strategies importers can use to mitigate risk in an increasingly volatile regulatory environment.
 
Key Timestamps:00:01 – Show introduction02:00 – The return of tariffs and long-term trade implications05:30 – How FDA-regulated goods are impacted by tariff changes08:15 – Increased FDA inspections and reallocation of resources11:10 – Industries most affected: food, cosmetics, medical devices, pharmaceuticals14:25 – The evolving relationship between FDA and Customs at U.S. ports18:20 – Common issues triggering shipment holds: labeling, documentation, and new inspector errors23:05 – Compliance risks when importing from China, India, and Mexico under USMCA27:40 – Labeling enforcement as a leading cause of FDA detentions31:10 – Practical steps importers can take to protect shipments and avoid costly delays34:55 – Key advice for navigating FDA and Customs scrutiny in 2024 and beyond
 
About the Show:FDA Imports Cross-Border Compliance is a podcast hosted by attorney Benjamin L. England, founder of FDAImports.com. The show helps importers, exporters, and global businesses navigate the complex legal and regulatory landscape at the U.S. border. With expert insights on FDA, Customs, USDA, DEA, and trade compliance, listeners gain practical strategies to protect their products and keep supply chains moving.

Episode Summary:In Episode 12, attorney Benjamin L. England breaks down urgent developments impacting FDA-regulated importers. From rising tariffs on pharmaceuticals and small-package imports to FDA staffing delays, Benjamin offers deep insight into the regulatory trends reshaping international trade. The discussion also covers evolving dietary supplement enforcement, state drug importation from Canada, and how businesses can adapt in a volatile regulatory climate.
 
Timestamps: 00:00 – Introduction and episode overview 01:00 – Pharmaceutical tariffs and valuation warnings 02:00 – De minimis abuse and postal surcharge increases 05:30 – FDA leadership shakeups and resulting delays 08:30 – ORA to OII: FDA reorganization and compliance officer authority 10:30 – FOIA backlogs and agency resource cuts 11:30 – CBP resources remain strong vs. FDA bottlenecks 12:00 – Operational impacts on importers: shipment delays, labeling scrutiny 13:30 – Ingredient disclosure, red dye regulations, and allergy concerns 14:30 – Consumer protection rationale for FDA involvement 15:00 – Peptides, Canadian drug imports, and upcoming policy shifts 17:00 – How importers can stay agile during regulatory uncertainty 18:00 – Final tips and why to monitor FDA budget and leadership
 
About the Show:FDA Imports: Cross-Border Compliance with Benjamin L. England is your front-line podcast for real-world insights into FDA, CBP, and international trade regulations. Hosted by veteran FDA attorney and strategist Benjamin L. England, each episode offers critical guidance for companies navigating border compliance, import law, and global supply chain risks.

Episode Summary:In this tactical episode, FDA regulatory attorney Benjamin L. England explains the critical differences between FDA import refusals and Customs and Border Protection (CBP) seizures, and what businesses can do when their products are detained, refused, or seized. From legal definitions to strategic responses and mistakes to avoid, Ben outlines how to protect your goods, your company, and your import privileges. Whether you're facing a Notice of FDA Action or a CBP Seizure Notice, this episode provides a step-by-step breakdown of how to respond, and when to escalate.
Timestamps: 00:00 – Introduction to Benjamin England and the topic 01:00 – Difference between an FDA refusal and a CBP seizure 02:30 – What triggers each enforcement action 04:00 – Deadlines and warning signs in detention notices 05:30 – First steps to take after receiving a notice 06:30 – Destruction vs. export procedures (including FDA supervision) 07:30 – Legal remedies: rescission, petition, or forfeiture 09:00 – Criteria for reversing FDA refusals 10:30 – When litigation is appropriate (or not) 12:30 – Why CBP is more litigation-friendly than FDA 13:30 – Most common mistakes importers make 15:00 – How CBP redelivery demands work after refusal 16:00 – When to hire an attorney for seizures or rescissions 17:00 – Compliance systems to avoid enforcement actions
About the Show:FDA Imports: Cross-Border Compliance with Benjamin L. England is your go-to source for practical legal guidance on FDA, CBP, and global trade compliance. Hosted by attorney and regulatory strategist Benjamin L. England, each episode offers actionable insight for importers, manufacturers, and international companies facing regulatory enforcement.

Episode Summary:
In this episode, Benjamin L. England discusses recent developments in pharmaceutical imports, commerce, and CBP tariffs, particularly focusing on Section 232 investigations and reciprocal tariffs. The conversation covers the Department of Commerce's role in regulating international trade and its recent investigation into pharmaceutical imports.
 
Key Timestamps:
00:00 - Show Introduction
00:34 - Discussion of reciprocal tariffs and previous predictions
03:53 - China's retaliation and precious metals trade
05:22 - Department of Commerce's role in trade regulation
08:21 - How Commerce investigations are initiated
11:10 - Impact on pharmaceutical development and import/export
15:24 - Future predictions for international trade relations
 
About the Show:
FDA Imports Cross-Border Compliance with Attorney Benjamin L. England is a podcast that explores legal challenges, compliance issues, and regulations affecting global trade. The show provides expert insights into FDA-related products including foods, drugs, cosmetics, and medical devices.